In addition, while short and medium term safety profiles from clinical trials are reassuring, long term cardiovascular, pancreatic, and endocrine safety data are still evolving
In the arena of healthcare, the interlinked epidemics of type 2 diabetes and obesity present a formidable challenge
10.1186/1471-2377-13-84 92 LedererC
7.2 Relaxin-3 and the behavioral dimension of metabolic disease Relaxin-3, a member of the relaxin peptide family predominantly expressed in the nucleus incertus, signals through the RXFP3 receptor and exerts pronounced effects on feeding behavior, arousal, stress responsiveness, and cognitive processing in animal models ( At first glance, this profile appears incompatible with obesity therapy
If you are considering GLP 1 therapy, bring three things to your consultation
Most are gastrointestinal, meaning stomach and digestive related